Subject(s)
Glucosyltransferases/genetics , Hyperpigmentation/genetics , Mutation , Skin Diseases, Genetic/genetics , Skin Diseases, Papulosquamous/genetics , DNA Mutational Analysis , Disease Progression , Female , Glucosyltransferases/metabolism , Humans , Hyperpigmentation/metabolism , Male , Signal Transduction , Skin Diseases, Genetic/metabolism , Skin Diseases, Papulosquamous/metabolismSubject(s)
Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Hemangiosarcoma/diagnosis , Neoplasms, Radiation-Induced/diagnosis , Skin Neoplasms/diagnosis , Thoracic Neoplasms/diagnosis , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Chemotherapy, Adjuvant , Combined Modality Therapy , Female , Hemangiosarcoma/pathology , Humans , Mastectomy, Segmental , Neoplasm Staging , Neoplasms, Radiation-Induced/pathology , Radiotherapy, Adjuvant/adverse effects , Skin/pathology , Skin Neoplasms/pathology , Thoracic Neoplasms/pathologyABSTRACT
BACKGROUND: Accumulating evidence suggests a critical role for increased reactive oxygen species (ROS) production in left ventricular (LV) remodeling and dysfunction after myocardial infarction (MI). Increased expression of xanthine oxidase (XO), a major source of ROS, has recently been demonstrated in experimental and clinical heart failure; however, a potential role for LV remodeling processes remains unclear. We therefore studied the effect of long-term treatment with allopurinol, a potent XO inhibitor, on myocardial ROS production and LV remodeling and dysfunction after MI. METHODS AND RESULTS: Mice with extensive anterior MI (n=105) were randomized to treatment with either vehicle or allopurinol (20 mg x kg(-1) x d(-1) by gavage) for 4 weeks starting on day 1 after surgery. Infarct size was similar among the groups. XO expression and activity were markedly increased in the remote myocardium of mice after MI, as determined by electron spin resonance spectroscopy. Myocardial ROS production was increased after MI but markedly reduced after allopurinol treatment. Importantly, allopurinol treatment substantially attenuated LV cavity dilatation and dysfunction after MI, as assessed by echocardiography, and markedly reduced myocardial hypertrophy and interstitial fibrosis. CONCLUSIONS: The present study reveals a novel beneficial effect of treatment with allopurinol, ie, a marked attenuation of LV remodeling processes and dysfunction after experimental MI. Allopurinol treatment therefore represents a potential novel strategy to prevent LV remodeling and dysfunction after MI.
Subject(s)
Allopurinol/therapeutic use , Myocardial Infarction/drug therapy , Ventricular Dysfunction, Left/prevention & control , Ventricular Remodeling/drug effects , Xanthine Oxidase/antagonists & inhibitors , Animals , Drug Evaluation, Preclinical , Fibrosis , Ligation , Male , Mice , Mice, Inbred C57BL , Myocardial Infarction/complications , Myocardial Infarction/pathology , Oxidative Stress , Random Allocation , Reactive Oxygen Species , Superoxides/metabolism , Ventricular Dysfunction, Left/etiology , Xanthine Oxidase/metabolismABSTRACT
BACKGROUND: Endothelial nitric oxide (eNO) bioavailability is severely reduced after myocardial infarction (MI) and in heart failure. Statins enhance eNO availability by both increasing eNO production and reducing NO inactivation. We therefore studied the effect of statin treatment on eNO availability after MI and tested its role for endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular (LV) dysfunction, remodeling, and survival after MI. METHODS AND RESULTS: Wild-type (WT) and eNO synthase (eNOS)-/- mice with extensive anterior MI were randomized to treatment with vehicle (V) or atorvastatin (Ator, 50 mg/kg QD by gavage) for 4 weeks starting on day 1 after MI. Ator markedly improved endothelium-dependent, NO-mediated vasorelaxation; mobilization of endothelial progenitor cells; and myocardial neovascularization of the infarct border in WT mice after MI while having no effect in eNOS-/- mice. LV dysfunction and interstitial fibrosis were markedly attenuated by Ator in WT mice, whereas no effect was observed in eNOS-/- mice after MI. Importantly, Ator significantly increased the survival rate during 4 weeks after MI in WT mice (Ator versus V, 80% versus 46%; P<0.01, n=75) but not in eNOS-/- mice (43% versus 48%; NS, n=42). CONCLUSIONS: These findings suggest that increased eNO availability is required for statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, LV dysfunction, interstitial fibrosis, and survival after MI. eNO bioavailability after MI likely represents an important therapeutic target in heart failure after MI and mediates beneficial effects of statin treatment after MI.
